MissionIR Articles
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Files IND Application for Berubicin in Treatment of GBM
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it has submitted an Investigational New…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Hosting Webcast for Discussion of Phase 2 Clinical Trial Design
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has scheduled a webcast today during which it will be discussing…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Unveil Adaptive Design for Berubicin Phase 2 Clinical Trial in Nov. 12 Webinar
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced its plans to issue a video update…
-
CNS Pharmaceuticals (NASDAQ: CNSP) Announces Completion of Drug Manufacturing for Brain Cancer Trial
Houston-based CNS Pharmaceuticals is preparing to launch Phase 2 clinical testing of a novel brain cancer-fighting drug candidate called Berubicin early next year The biopharmaceutical company recently announced that a U.S.-based company contracted to make…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Completion of Drug for Clinical Trials
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has through its European manufacturer, BSP Pharmaceuticals S.p.A. (“BSP”), finished manufacturing…
-
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moves Closer to IND Filing as Manufacturing of Lead Drug Candidate Commences
Berubicin Expected to Commence Trials for the Treatment of Glioblastoma, An Aggressive Form of Brain Cancer Currently Considered Incurable Production of Berubicin Begins in the U.S. and Europe Dual Manufacturing Facilities Engaged to Reduce Supply…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Completion of Manufacturing of Lead Drug Candidate
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has completed the manufacturing process for Berubicin Drug Product. CNSP’s U.S.…
-
MissionIRNewsBreaks – Why CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Is ‘One to Watch’
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. A recent article discussing CNS Pharmaceuticals reads, “The…
-
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Takes Another Step Closer to Q1 Launch of Brain Cancer Drug Trial
CNS Pharmaceuticals is a pre-clinical-stage developer of novel brain cancer-fighting drugs, including its lead candidate Berubicin The company is working to build on promising results from a 2006 Phase I trial, which provided 44 percent…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights New Glioblastoma-Focused Segment Airing on Lifetime TV
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today highlighted a new segment from The Balancing Act…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Begins Manufacturing of Lead Drug Candidate in Europe
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its European manufacturer, BSP Pharmaceuticals S.p.A.…
-
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Partnership with Imaging Specialists IAG Gives Tech Boost to Upcoming Brain Cancer Drug Trials
Clinical-stage biotech developer CNS Pharmaceuticals is working to demonstrate the potential effectiveness of its novel drug, Berubicin, in treating aggressive and rare brain cancer glioblastoma multiforme (“GBM”) CNS expects to launch Phase II trials of…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Achieves Critical Milestone for Production of Lead Drug Candidate
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its GMP manufacturer partner NCK A/S,…
-
CNS Pharmaceuticals, Inc. (CNSP) Expands Scientific Advisory Board with Leading Neuro-Oncology Expert, Dr. Patrick Wen, M.D.
Pivotal Phase 2 Berubicin trial expected to commence in Q1 2021 following planned IND submission in Q4 2020 CNS Pharmaceuticals also plans to begin pre-clinical work on Berubicin in connection with treatment for lymphomas, pancreatic,…
-
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is “One to Watch”
CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and currently incurable form of brain cancer. In a Phase I clinical trial of Berubicin in malignant brain…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Partners with Leading Medical Imaging Group for Upcoming Berubicin Clinical Trials
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has announced that it will partner with Image Analysis Group (“IAG”)…
-
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Mines Investment-building Opportunity for Brain Tumor-Targeting Drug Candidate at Annual Conference
CNS Pharmaceuticals is a clinical-stage biotechnology company developing therapies to combat aggressive cancers of the brain and central nervous system The company will be applying for approval to launch Phase II trials in the first…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP), Sub-Licensee Partner Advancing Lead Drug Candidate in First-Ever Phase 1 and Phase 2 Clinical Trials
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing its leading drug candidate, Berubicin, to move…
Search Articles
Latest Articles
- MissionIRNewsBreaks – XTI Aerospace, Inc. (NASDAQ: XTIA) Announces Acquisition of Drone Nerds and $25M Strategic Investment Led by Unusual Machines
- MissionIRNewsBreaks – Massimo Group (NASDAQ: MAMO) Receives More Than 4,000 Unit Orders Totaling Over $20 Million for Q4
- MissionIRNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Highlights Strategic Growth Vision Through Datavault Insights
- MissionIRNewsBreaks – Micropolis Holding Co. (NYSE American: MCRP) Featured on New Episode of IBN’s TechMediaWire Podcast
- MissionIRNewsBreaks – Beeline Holdings, Inc. (NASDAQ: BLNE) Closes $7.4M Registered Direct as Company Targets Cash Flow Positive in Q1 2026